Annonaceous acetogenins mediated up-regulation of Notch2 exerts growth inhibition in human gastric cancer cells in vitro
Metrics: PDF 1437 views | HTML 2275 views | ?
Yan Li1, Jianbin Ye1, Zhongbiao Chen1, Junjie Wen1, Fei Li1, Pengpeng Su1, Yanqing Lin1, Bingxin Hu1, Danlin Wu1, Lijun Ning1, Qi Xue2, Hongxiang Gu2, Yunshan Ning1
1School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, PR. China
2Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR. China
Yunshan Ning, email: [email protected]
Yan Li, email: [email protected]
Keywords: annonaceous acetogenins, gastric cancer cell, Notch2, proliferation, apoptosis
Received: December 22, 2016 Accepted: February 08, 2017 Published: February 18, 2017
Background: Gastric cancer (GC) is a global health problem because of limited treatments and poor prognosis. Annonaceous acetogenins (ACGs) has been reported to exert anti-tumorigenic effects in cancer, yet the mechanism underlying its effects on GC remains largely unknown. Notch signaling plays a critical role in cell proliferation, differentiation and apoptosis. Therefore, it may contribute to the development of GC. This study aims to explore the role of Notch2 in ACGs’ activities in GC cells.
Results: ACGs inhibited GC cells’ viability in a dose dependent manner and led to cell apoptosis and cell cycle arrest in G0/G1 phase with an increased Notch2 expression. Additionally, Notch2 siRNA reduced ACGs-induced cell growth inhibition while Notch2 cDNA transfection did the opposite.
Materials and Methods: ACGs were administrated in GC cells and cell proliferation was assayed by MTS, cell apoptosis and cell cycle were detected by flow cytometry. Additionally, the expression of Notch2 and the downstream target Hes1 were identified by Western blot. Furthermore, Notch2-siRNA transfection and Notch2-cDNA were performed to investigate the role of Notch2 in the antitumor effect of ACGs. Conclusions: Up-regulation of Notch2 by ACGs is a potential therapeutic strategy for GC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.